Site Map

• Health Care Providers
  • Antibody in Plasma
    • Antibody in Plasma
  • Weighing the Evidence
    • Weighing the Evidence
  • Component 1: Rapid Evaluation Program
    • Component 1: Rapid Evaluation Program
  • Treatment-Control Study
  • Component 3: Clinical Trials
    • Component 3: Clinical Trials
    • Protocols for pediatrics
    • Protocol for asymptomatic contacts
    • Protocol for mild/moderate illness
    • Protocol for severe/critical illness
    • Protocols for Outpatients Infected
  • hyperimmune_globulin
    • Hyperimmune Globulin
  • Working with Plasma Donors
    • Linking Donors to Providers
  • Regulatory Issues
    • Regulatory Issues
  • Health Care Providers
  • Endorsements
  • International use of CCP
  • Who are we?
    • Who are we?
    • Participating Institutions
    • Investigators
    • Basic Principles
• Virology
  • Virology
  • Antibody Detection
  • Virus Detection
  • COVID-19 Serology Tests Performance Measures
  • COVID-19 molecular test performance measures
  • Pregnancy and Antibodies
  • Vaccine and Antibodies
• Uses of Plasma
  • Donor Stories
    • Donor Stories
    • New York’s Angel of Life
  • Donating and Using Plasma
• Seeking Treatment
  • Seeking Treatment
• Key Scientific Papers
  • Key Scientific Papers
• Home
• News
  • IDSA Supports FDA Action on Emergency Investigational Convalescent Plasma Treatment for COVID-19
  • Statement From the Presidents of the NAS, NAE, and NAM Supporting Steps Necessary to Assess the Potential for Human Convalescent Plasma to Help Control COVID-19
  • New York Blood Center to Collect First Blood Plasma Donations from Recovered COVID-19 Patients to Treat Severe Cases
  • FDA Licenses First COVID-19 Anti-body Test
  • News
• Antibodies
  • Antibodies
• Contact Us
• Privacy Statement
• Site Accessibility
• Site Map
• Search
• Give